drugset / Trial / NCT05461365

Intranasal Insulin for COVID-19-related Smell Loss

NCT05461365

Phase 3 Completed 27 enrolled Universidad Panamericana
NaSingle-groupOpen-labelTreatment

Summary

The aim of this study was to quantify the improvement in olfaction of 27 post-COVID-19 patients, after three intreventions of intranasal insulin during a four week period, with the help of the Threshold, Discrimination and Identification (TDI) score evaluated with Sniffin Sticks®.

Timeline

Start
2021-01-04
Primary completion
2021-11-25
Completion
2021-12-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin Protein / enzyme biologic 40 iu Intranasal

Indications